FDA Grants Accelerated Approval to Bizengri for NSCLC and Pancreatic Adenocarcinoma

The FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with the ...

DECEMBER 5, 2024